Genmab's Epcoritamab Trial Results Lead to Stock Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy GMAB?
Source: seekingalpha
Genmab A/S's stock fell 5.47% today, hitting a 5-day low amid broader market weakness with the Nasdaq-100 down 0.14% and the S&P 500 down 0.02%.
The decline follows the announcement of the EPCORE DLBCL-1 trial results for Epcoritamab, which showed a significant improvement in progression-free survival (PFS) with a hazard ratio of 0.74. However, the lack of statistically significant overall survival improvement raised investor concerns, leading to a 7% drop in stock price. Despite the promising PFS results, the market reacted negatively due to the overall survival data not meeting expectations.
This situation highlights the challenges Genmab faces in gaining investor confidence despite advancements in treatment options for patients with relapsed or refractory DLBCL. The company plans to engage with global regulatory authorities to discuss future steps for Epcoritamab, which may influence its market position moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 26.180
Low
26.00
Averages
38.50
High
48.00
Current: 26.180
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genmab Major Shareholder Announcement
- Major Shareholder Change: As of May 8, 2026, Orbis Investment Management Limited controls 5.08% of Genmab A/S's voting rights through 3,166,357 shares, which may influence the company's governance structure and shareholder decisions.
- Company Background: Genmab is an international biotechnology company dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, showcasing over 25 years of R&D experience and strong market competitiveness.
- Product Pipeline: Genmab is advancing multiple late-stage clinical programs aimed at delivering transformative medicines to patients, which not only enhances the company's market position but also lays the groundwork for future revenue growth.
- Risk Factors Highlighted: The announcement includes forward-looking statements that emphasize various risks associated with clinical development and market acceptance, prompting investors to consider these uncertainties when assessing the company's long-term investment value.
See More
Genmab Reports 25% Revenue Growth in Q1
- Significant Revenue Growth: Genmab reported Q1 revenue of $896 million, up $181 million or 25% from $715 million in Q1 2025, primarily driven by increased DARZALEX® and Kesimpta® royalties from collaborations with Johnson & Johnson and Novartis.
- Sales Performance Boost: The rise in net product sales of EPKINLY further contributed to overall revenue growth, indicating Genmab's strong market performance and sustained product demand.
- Robust Operating Profit: Excluding acquisition and integration-related charges and amortization of acquired intangible assets, Genmab's operating profit stood at $237 million, reflecting effective cost management and enhanced profitability.
- Optimistic Market Outlook: Genmab confirmed Q1 DARZALEX sales of $3.96 billion, driven by strong demand in the U.S., suggesting further growth potential and market share expansion for the company in the future.
See More
Genmab to Announce Q1 Earnings on May 7
- Earnings Announcement: Genmab (GMAB) is set to release its Q1 earnings on May 7 before market open, with consensus EPS estimates at $0.17 and revenue expectations of $889.15 million, providing crucial financial health indicators for investors.
- Strong Sales Performance: Genmab confirmed Q1 DARZALEX sales of $3.96 billion, driven primarily by robust demand in the U.S., which not only exceeds market expectations but could also lead to a potential increase in the company's stock price.
- Market Environment Impact: Amid disruptions in the Middle East, over $10 billion in healthcare stocks on Wall Street are considered oversold, and Genmab's financial performance may attract renewed investor interest in the sector, influencing overall market sentiment.
- Future Outlook: With the upcoming earnings report, investors will closely monitor Genmab's performance and future guidance to assess its ongoing growth potential in the highly competitive biopharmaceutical market.
See More
Latest Rating Changes on Wall Street
- Airbnb Upgrade: Wells Fargo upgraded Airbnb from equal weight to overweight, projecting revenue growth of 6% to 11% and EPS growth of 7% to 12% by 2027, indicating strong innovation and market potential.
- Positive Outlook for SharonAI: Compass Point initiated coverage on SharonAI with a buy rating, highlighting that its first major contract will drive scale and that its Australian capacity build provides a credible market base for deployment.
- Biogen's Multiple Catalysts: UBS upgraded Biogen to buy with a price target of $225, citing increasing confidence in several pipeline catalysts expected to drive stock price higher over the next 12-15 months.
- Twilio's Strategic Improvement: Bank of America upgraded Twilio from underperform to buy with a price target of $190, believing its strategic positioning in AI will lead to positive growth inflections for the company.
See More
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
Genmab Major Shareholder Announcement
- Major Shareholder Change: As of May 8, 2026, Orbis Investment Management Limited controls 5.08% of Genmab A/S's voting rights through 3,166,357 shares, which may influence the company's governance structure and shareholder decisions.
- Company Background: Genmab is an international biotechnology company dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, showcasing over 25 years of R&D experience and strong market competitiveness.
- Product Pipeline: Genmab is advancing multiple late-stage clinical programs aimed at delivering transformative medicines to patients, which not only enhances the company's market position but also lays the groundwork for future revenue growth.
- Risk Factors Highlighted: The announcement includes forward-looking statements that emphasize various risks associated with clinical development and market acceptance, prompting investors to consider these uncertainties when assessing the company's long-term investment value.
See More
Genmab Reports 25% Revenue Growth in Q1
- Significant Revenue Growth: Genmab reported Q1 revenue of $896 million, up $181 million or 25% from $715 million in Q1 2025, primarily driven by increased DARZALEX® and Kesimpta® royalties from collaborations with Johnson & Johnson and Novartis.
- Sales Performance Boost: The rise in net product sales of EPKINLY further contributed to overall revenue growth, indicating Genmab's strong market performance and sustained product demand.
- Robust Operating Profit: Excluding acquisition and integration-related charges and amortization of acquired intangible assets, Genmab's operating profit stood at $237 million, reflecting effective cost management and enhanced profitability.
- Optimistic Market Outlook: Genmab confirmed Q1 DARZALEX sales of $3.96 billion, driven by strong demand in the U.S., suggesting further growth potential and market share expansion for the company in the future.
See More
Genmab to Announce Q1 Earnings on May 7
- Earnings Announcement: Genmab (GMAB) is set to release its Q1 earnings on May 7 before market open, with consensus EPS estimates at $0.17 and revenue expectations of $889.15 million, providing crucial financial health indicators for investors.
- Strong Sales Performance: Genmab confirmed Q1 DARZALEX sales of $3.96 billion, driven primarily by robust demand in the U.S., which not only exceeds market expectations but could also lead to a potential increase in the company's stock price.
- Market Environment Impact: Amid disruptions in the Middle East, over $10 billion in healthcare stocks on Wall Street are considered oversold, and Genmab's financial performance may attract renewed investor interest in the sector, influencing overall market sentiment.
- Future Outlook: With the upcoming earnings report, investors will closely monitor Genmab's performance and future guidance to assess its ongoing growth potential in the highly competitive biopharmaceutical market.
See More
Latest Rating Changes on Wall Street
- Airbnb Upgrade: Wells Fargo upgraded Airbnb from equal weight to overweight, projecting revenue growth of 6% to 11% and EPS growth of 7% to 12% by 2027, indicating strong innovation and market potential.
- Positive Outlook for SharonAI: Compass Point initiated coverage on SharonAI with a buy rating, highlighting that its first major contract will drive scale and that its Australian capacity build provides a credible market base for deployment.
- Biogen's Multiple Catalysts: UBS upgraded Biogen to buy with a price target of $225, citing increasing confidence in several pipeline catalysts expected to drive stock price higher over the next 12-15 months.
- Twilio's Strategic Improvement: Bank of America upgraded Twilio from underperform to buy with a price target of $190, believing its strategic positioning in AI will lead to positive growth inflections for the company.
See More
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
